<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1122490742015118&amp;ev=PageView&amp;noscript=1">
TV_PRN_Tagline_Logo

As part of the PBI Companies Family TriviumVet are proud to partner with our sister brand PRN Pharmacal to commercialise and distribute our products.

To learn more about their product portfolio visit www.prnpharmacal.com

liavium blog banner final

TriviumVet Secures FDA Conditional Approval for Liavium-CA1

Felycin®-CA1

Felycin®-CA1

Felycin®-CA1 (sirolimus delayed release tablets), administered once weekly, is indicated for the management of ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy (HCM). 

This is the first Conditionally Approved drug for the treatment of Feline HCM.

Liavium

Liavium-CA1

Liavium-CA1 (pregabalin chewable tablets) - Analgesic for oral use in dogs only.

Indicated for the control of pain and clinical signs associated with Chiari-Like Malformation and Syringomyelia in dogs.

30mg, 90mg, 180mg tablets (90mg tablets are SCORED) - Market launch coming soon

The TriviumVet
WHY?

Every day we are awakened by a rousing purr, an energetic bark, or a slobbery kiss is a great day as far as we’re concerned. We do what we do for mornings like this, to help the pets we love live better quality, longer lives. 

What gets us up in the morning?

OUR WHY is to bridge the treatment gaps in veterinary healthcare for our pets

OUR MISSION is to deliver innovative healthcare solutions for cats and dogs 

OUR VISION as a company is to have a valuable impact on global pet healthcare

Pioneers in Animal Health - TriviumVet feature on Viewpoint with Dennis Quaid